0001415889-24-001754.txt : 20240124
0001415889-24-001754.hdr.sgml : 20240124
20240124163941
ACCESSION NUMBER: 0001415889-24-001754
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240122
FILED AS OF DATE: 20240124
DATE AS OF CHANGE: 20240124
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Macrae Sandy
CENTRAL INDEX KEY: 0001675687
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 24556969
MAIL ADDRESS:
STREET 1: 721 ST. GEORGES ROAD
CITY: PHILADELPHIA
STATE: PA
ZIP: 19119
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94084
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94084
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
form4-01242024_090135.xml
X0508
4
2024-01-22
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001675687
Macrae Sandy
C/O SANGAMO THERAPEUTICS, INC.
501 CANAL BLVD.
RICHMOND
CA
94084
true
true
false
false
PRESIDENT, CEO AND DIRECTOR
0
Common Stock
2024-01-22
4
A
0
2000000
0
A
2592476
D
Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will vest as to one-half (1/2) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 4 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through each such date and subject to acceleration in full in the event of a Change in Control (as defined in the 2018 EIP).
Includes: (a) 46,134 shares subject to the Reporting Person's February 25, 2021 RSU grant that will vest in one final installment on February 25, 2024, (b) 105,000 shares subject to the Reporting Person's February 25, 2022 RSU grant that will vest in successive equal quarterly installments through February 25, 2025, and (c) 157,300 shares subject to Reporting Person's February 24, 2023 RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter. The vesting of all such RSU grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
/s/ Ron A. Metzger, Attorney-in-Fact
2024-01-24